Breaking Finance News

Incyte INCY (NYSE:INCY) target price raised to $136.00, issued a report today by RBC Capital Markets

Incyte INCY (NYSE:INCY) had its price target upped to $136.00 by RBC Capital Markets in an issued report issued 9/15/2017. The upped price target implies a potential upside of 0.14% based on the company's previous stock price.

Just yesterday Incyte INCY (NYSE:INCY) traded -0.27% lower at $119.59. INCY’s 50-day average is $127.79 and its two hundred day average is $130.32. With the last close down -8.35% relative to the two hundred day average, compared with the S&P 500 Index which has increased 0.04% over the date range. Volume of trade was down over the average, with 841,290 shares of INCY changing hands under the typical 1,362,460

Performance Chart

Incyte INCY (NYSE:INCY)

With a total market value of $0, Incyte INCY has with a one year low of $79.75 and a one year high of $153.15 .

A total of 14 analysts have released a research note on INCY. Seven analysts rating the company a strong buy, eight analysts rating the company a buy, one analyst rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a one year target of $91.36.

More About Incyte INCY (NYSE:INCY)

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.